Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 13/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.38 |
| ▸ | USP7 | Q93009 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.35 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.35 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12670774 | 0.80 | SSTR4 (0.40) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL24377456 | 0.77 | P2RX3 (0.35) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL16255896 | 0.75 | SSTR4 (0.48) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL16255906 | 0.75 | SSTR4 (0.49) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL19724807 | 0.75 | SSTR4 (0.49) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL31740327 | 0.74 | SSTR4 (0.51) | KDM4EALDH1A1GLAGAAHPGD | |
| Hydrochloric Acid SCHEMBL28675219 | 0.74 | SSTR4 (0.47) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL22692923 | 0.73 | KDM4E (0.42) | KDM4EALDH1A1GLAGAAHPGD | |
| SCHEMBL16255996 | 0.73 | SSTR4 (0.48) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL25791384 | 0.72 | SSTR4 (0.43) | SSTR4SSTR1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022086920-A1 | GLUTAMINYL-PEPTIDE CYCLOTRANSFERASE LIKE (QPCTL) PROTEIN INHIBITORS AND USES THEREOF | BLACKSMITH MEDICINES, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| US-7863269-B2 | protease-activated receptor 1 (PAR1) inhibitors such as 1-(3,5-di-tert-butyl-4-hydroxyphenyl)-2-(3-iminoimidazo[1,5-a]pyridin-2-yl)ethanone, used as anticoagulants | SANOFI-AVENTIS (FR) | 2011-01-04 | — | — | US | disclosed |
| EP-2054412-B1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI AVENTIS (FR) | 2009-12-02 | — | — | EP | disclosed |
| EP-2054412-B1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI AVENTIS (FR) | 2009-12-02 | — | — | EP | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-07-30 | — | — | US | disclosed |
| EP-2054412-A2 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008014888-A2 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2008-02-07 | — | — | WO | disclosed |
| WO-2008014888-A2 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192150-A1 | IMINO-IMIDAZO-PYRIDINE DERIVATIVES HAVING ANTITHROMBOTIC ACTIVITY | F2R, TFPI, F2RL1 | KDM4E 4314/4885ALDH1A1 504/4885GLA 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.